Unknown

Dataset Information

0

Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing Analysis.

ABSTRACT: We experienced two cases of hepatitis C virus (HCV) eradication failure in patients with a history of non-responsiveness to previous treatments with direct-acting antiviral agents (DAAs) who were subsequently treated with the combination of glecaprevir and pibrentasvir (GLE/PIB). Direct sequencing at commencement of GLE/PIB therapy showed non-structural protein (NS) 5A-P32 deletion in the first patient and NS5A-R30E/Q54H/A92K in the second patient (both genotype 1b). The common point was that L31/Y93 was double wild-type, and the IL28B polymorphism was non-TT type. Even when L31/Y93 is double wild-type, other NS5A mutations may affect the DAA re-treatment outcome. We analyzed the transition of amino acid mutations at NS5A by ultra-deep sequencing.

SUBMITTER: Sano T 

PROVIDER: S-EPMC6794189 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing Analysis.

Sano Tomoya T   Akuta Norio N   Suzuki Fumitaka F   Kasuya Kayoko K   Fujiyama Shunichiro S   Kawamura Yusuke Y   Sezaki Hitomi H   Hosaka Tetsuya T   Saitoh Satoshi S   Kobayashi Masahiro M   Suzuki Yoshiyuki Y   Kobayashi Mariko M   Arase Yasuji Y   Ikeda Kenji K   Kumada Hiromitsu H  

Internal medicine (Tokyo, Japan) 20190607 18

We experienced two cases of hepatitis C virus (HCV) eradication failure in patients with a history of non-responsiveness to previous treatments with direct-acting antiviral agents (DAAs) who were subsequently treated with the combination of glecaprevir and pibrentasvir (GLE/PIB). Direct sequencing at commencement of GLE/PIB therapy showed non-structural protein (NS) 5A-P32 deletion in the first patient and NS5A-R30E/Q54H/A92K in the second patient (both genotype 1b). The common point was that L3  ...[more]

Similar Datasets

Unknown Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.
| S-EPMC5901397 | biostudies-literature
Unknown Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
| S-EPMC5573922 | biostudies-literature
Unknown Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Patients With Previous Direct-Acting Antiviral Therapy Failures: A Meta-Analysis.
| S-EPMC7793883 | biostudies-literature
Unknown In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir.
| S-EPMC5404558 | biostudies-literature
Unknown The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment.
| S-EPMC6478991 | biostudies-literature
Unknown Retreatment Options Following HCV Direct Acting Antiviral Failure.
| S-EPMC5726279 | biostudies-literature
Unknown Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan.
| S-EPMC8648748 | biostudies-literature
Unknown Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
| S-EPMC6220874 | biostudies-literature
Unknown Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent.
| S-EPMC4391872 | biostudies-literature
Unknown Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.
| S-EPMC5814891 | biostudies-other